David E Einspahr MD

Oncology•Topeka, KS

Hematologic Oncology, Neuro-Oncology

Practicing Hematologist & Oncologist at Stormont Vail Regional Health Center, Stormont Vail West

Join to View Full Profile

1414 Sw 8th AveTopeka, KS 66606
Phone+1 785-354-5300
Fax+1 785-354-5309

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1986
University of Kansas School of MedicineFellowship, Allergy and Immunology, 1983 - 1984
University of Kansas School of MedicineResidency, Internal Medicine, 1980 - 1983
University of Nebraska College of MedicineClass of 1980

Certifications & Licensure

KS State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
ACTIVE_NOT_RECRUITING
PHASE3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
ACTIVE_NOT_RECRUITING
PHASE3
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2, Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.
Ronald K. Potkul, Joseph M. Unger, Robert B. Livingston, Katherine D. Crew, Sharon P. Wilczynski
NPJ Breast Cancer. 2016-08-10
303 citations
Intact transferrin receptors in human plasma and their relation to erythropoiesis.
H. A. Huebers, Yves Beguin, Pensri Pootrakul, David Einspahr, Clement A. Finch
Blood. 1990-01-01